Clinical Trials
Recent cancer clinical trials sourced from ClinicalTrials.gov. Trials are listed for informational purposes only. Always consult your healthcare provider before making decisions about clinical trial participation.
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Conditions: Melanoma, Cutaneous Malignant
Interventions: IMA203, nivolumab plus relatlimab, lifileucel, nivolumab, pembrolizumab, ipilimumab, Dacarbazine, temozolomide, paclitaxel, paclitaxel plus carboplatin, Albumin-Bound Paclitaxel
NCT06743126 - View on ClinicalTrials.gov →DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Conditions: Ovarian Cancer, Ovarian Carcinoma, Recurrent Ovary Cancer, Recurrent Platinum-Resistant Ovarian Carcinoma
Interventions: DT2216, Paclitaxel
NCT06964009 - View on ClinicalTrials.gov →Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → in Adult Participants With Metastatic Colorectal Cancer
Conditions: Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Rectal Diseases, Colorectal Neoplasms
Interventions: PF-08634404, Bevacizumab, ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →
NCT07222800 - View on ClinicalTrials.gov →Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant Therapy for Rectal Cancer
Conditions: Locally Advanced Rectal Cancer (LARC)
Interventions: Personalized ctDNA-MRD Detection
NCT07393048 - View on ClinicalTrials.gov →Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Conditions: Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer, Soft Tissue Sarcoma
Interventions: 68Ga-NNS309, 177Lu-DFC413
NCT07261631 - View on ClinicalTrials.gov →Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
Conditions: Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions: Imiquimod, Pembrolizumab, Sotigalimab, Synthetic Tumor-Associated Peptide Vaccine Therapy, Computed Tomography, Magnetic Resonance Imaging
NCT02600949 - View on ClinicalTrials.gov →A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCAGenes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation → MutationA change in DNA sequence that can drive cancer development.Click for full explanation →
Conditions: Prostate Cancer
Interventions: Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
NCT06952803 - View on ClinicalTrials.gov →WATER IV Prostate Cancer
Conditions: Localized Prostate Cancer
Interventions: Aquablation Therapy, Radical Prostatectomy
NCT06651632 - View on ClinicalTrials.gov →Comparison of Radical Prostatectomy Performed by Robot-assisted Laparoscopy or Conventional Laparoscopy or by Laparotomy
Conditions: Prostate Cancer
Interventions: assessment of urinary function and erectil function before and after prostatectomy
NCT04638088 - View on ClinicalTrials.gov →Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Conditions: Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Interventions: Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel
NCT07246863 - View on ClinicalTrials.gov →Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
Conditions: Small Cell Lung Carcinoma
Interventions: Durvalumab
NCT06992609 - View on ClinicalTrials.gov →Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Cemiplimab, Platinum based chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →, Stereotactic body radiation therapy
NCT06623656 - View on ClinicalTrials.gov →ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Conditions: Breast Neoplasms
Interventions: Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine, Carboplatin, Eribulin, Matching placebo
NCT07173751 - View on ClinicalTrials.gov →DCE-MRI and MBI in Assessing Tumor Response to ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → in Patients With Triple Negative Breast Cancer
Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Triple-Negative Breast Carcinoma
Interventions: Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Laboratory BiomarkerA measurable biological signal used to detect disease or predict treatment response.Click for full explanation → Analysis, Scintimammography, Technetium Tc-99m Sestamibi
NCT02744053 - View on ClinicalTrials.gov →Mindfulness Intervention for Improving Nutrition in the Digital Kitchen Among Stage I-III Breast Cancer Survivors, MIND Trial
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions: Behavioral Dietary Intervention, Best Practice, Electronic Medical Record, Questionnaire Administration
NCT06643455 - View on ClinicalTrials.gov →Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery
Conditions: Body Mass Index Greater Than or Equal to 30, Malignant Breast Neoplasm, Mammoplasty Patient, Obesity
Interventions: Negative Pressure Wound Therapy, Wound Care Management
NCT04003038 - View on ClinicalTrials.gov →Aerosolized Aldesleukin in Treating Patients With Lung Metastases
Conditions: Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Metastatic Osteosarcoma, Metastatic Renal Cell Cancer, Sarcoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Osteosarcoma AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions: Aerosolized Aldesleukin, Laboratory BiomarkerA measurable biological signal used to detect disease or predict treatment response.Click for full explanation → Analysis
NCT01590069 - View on ClinicalTrials.gov →A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
Interventions: BMS-986500, Palbociclib, Fulvestrant
NCT06997029 - View on ClinicalTrials.gov →A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Conditions: Prostatic Cancer, Castration-Resistant
Interventions: JSB462, AAA617
NCT07047118 - View on ClinicalTrials.gov →Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Conditions: Advanced Solid Tumors
Interventions: M7437, M7437
NCT07360314 - View on ClinicalTrials.gov →A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Conditions: Advanced Solid Tumors
Interventions: BAY3375968, Pembrolizumab
NCT05537740 - View on ClinicalTrials.gov →A Study of Disitamab Vedotin in Adults With HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation → Expressing Advanced Breast Cancer
Conditions: Breast Cancer, Breast Neoplasms
Interventions: Disitamab vedotin
NCT06966453 - View on ClinicalTrials.gov →A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen ReceptorA type of immunotherapy that genetically engineers a patient's own T cells to recognise and destroy cancer cells.Click for full explanation → T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...
Conditions: B-All, Acute Lymphoblastic Leukemia
Interventions: NGS testing
NCT05621291 - View on ClinicalTrials.gov →Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Conditions: Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer, Hematological Neoplasms, Hematopoietic Malignancies, Dysmyelopoietic Syndromes, Hematopoetic Myelodysplasia, Myeloid Leukemia, Acute, Nonlymphoblastic Leukemia, Acute, Leukemia, Lymphocytic, Acute
Interventions: aldesleukin, cyclophosphamide, fludarabine phosphate, Individual Patient TCR-Transduced PBL, TruSight Oncology (TSO) 500
NCT06904066 - View on ClinicalTrials.gov →A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Interventions: Opevesostat, Dexamethasone, Fludrocortisone acetate, Hydrocortisone, Abiraterone acetate, Prednisone acetate, Enzalutamide
NCT06136650 - View on ClinicalTrials.gov →Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
Conditions: Lung Cancer Stage III
Interventions: IBI308, Bevacizumab, Pemetrexed, Carboplatin, Thoracic surgery
NCT03872661 - View on ClinicalTrials.gov →FMD and Neoadjuvant Chemo-immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → in TNBC
Conditions: Breast Cancer
Interventions: Fasting-mimicking diet, ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →, Toripalimab
NCT07378306 - View on ClinicalTrials.gov →Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF MutationA change in DNA sequence that can drive cancer development.Click for full explanation →
Conditions: Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Interventions: Cetuximab, Encorafenib, Nivolumab
NCT05308446 - View on ClinicalTrials.gov →Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Conditions: Extensive Stage Lung Small Cell Carcinoma
Interventions: Atezolizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy
NCT04402788 - View on ClinicalTrials.gov →FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine TherapyTreatments that reduce or block hormones that fuel certain cancers.Click for full explanation →
Conditions: HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Laboratory BiomarkerA measurable biological signal used to detect disease or predict treatment response.Click for full explanation → Analysis, Positron Emission Tomography
NCT02398773 - View on ClinicalTrials.gov →Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
Conditions: Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions: Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Capivasertib, Cediranib Maleate, Computed Tomography, Durvalumab, Echocardiography Test, Multigated Acquisition Scan, Olaparib
NCT03660826 - View on ClinicalTrials.gov →Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Conditions: Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Endometrial Carcinoma
Interventions: Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
NCT05112601 - View on ClinicalTrials.gov →APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1Genes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →, BRCA2Genes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation → or PALB2 MutationA change in DNA sequence that can drive cancer development.Click for full explanation →
Conditions: Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Squamous Cell Carcinoma, Resectable Pancreatic Acinar Cell Carcinoma, Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Carcinoma
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Placebo Administration
NCT04858334 - View on ClinicalTrials.gov →Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
Conditions: Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm, Stage III Pancreatic Neuroendocrine Tumor AJCC v8, Stage IV Pancreatic Neuroendocrine Tumor AJCC v8, Unresectable Pancreatic Neuroendocrine Tumor
Interventions: Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Positron Emission Tomography, Sunitinib Malate
NCT05687123 - View on ClinicalTrials.gov →Collection of Blood From Patients With Cancer
Conditions: Prostate Cancer, Breast Cancer, Colon Cancer, Lung Cancer, Liver Cancer
NCT00034216 - View on ClinicalTrials.gov →Testing the Addition of a Type of Drug Called ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → to the Usual ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Conditions: Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Echocardiography Test, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Observation Activity, Paclitaxel, Pembrolizumab, Pemetrexed Disodium, Questionnaire Administration
NCT04267848 - View on ClinicalTrials.gov →Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Clinical Observation, Computed Tomography, Crizotinib, Cytology Specimen Collection Procedure, Echocardiography Test, Erlotinib, Gemcitabine Hydrochloride, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Placebo Administration, Positron Emission Tomography
NCT02194738 - View on ClinicalTrials.gov →Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Conditions: Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Durvalumab, Echocardiography Test, Iadademstat, Magnetic Resonance Imaging, Multigated Acquisition Scan
NCT06287775 - View on ClinicalTrials.gov →Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Conditions: Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Bevacizumab, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Osimertinib
NCT04181060 - View on ClinicalTrials.gov →Targeted TherapyDrugs that block specific molecules that cancer cells need to grow.Click for full explanation → Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Conditions: Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
Interventions: Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Fulvestrant, Ipatasertib, Leucovorin, Magnetic Resonance Imaging, Multigated Acquisition Scan, MutationA change in DNA sequence that can drive cancer development.Click for full explanation → Carrier Screening, Neratinib Maleate, Nilotinib Hydrochloride Monohydrate, Olaparib, Oxaliplatin, Paclitaxel, Palbociclib, Panitumumab, Positron Emission Tomography, Selumetinib Sulfate, Sotorasib
NCT05564377 - View on ClinicalTrials.gov →